Cure My Disease

Don't miss your cure!

 Log in / Sign up

Five-second sprints on a bike: a new test for multiple sclerosis symptoms

NCT ID NCT07804264

Disease control Sponsor: Universidad de León Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether short sprint interval training, involving repeated 5-second high-intensity cycling bursts, can improve walking, strength, fatigue, and cognitive speed in people with multiple sclerosis. Participants are randomly assigned to either the sprint program or their usual physical activity for two weeks. Researchers measure changes in walking tests, muscle strength, fatigue scales, and cognitive processing before and after the training. The goal is to see if this brief, time-efficient exercise approach offers meaningful benefits for managing MS symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Short sprint interval training on a recumbent cycle ergometer
What this could lead to
If it works, this could offer a time-efficient exercise strategy to improve physical function, fatigue, and cognitive processing speed in people with multiple sclerosis.
What could go wrong
This is a small, early-stage trial with only 40 participants and a short 2-week intervention, so results may not apply broadly. High-intensity exercise carries risks of injury or fatigue, and the training may not produce lasting benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of multiple sclerosis according to the revised McDonald criteria; Expanded Disability Status Scale score 0-3.5. * Age 18-65 years. * No multiple sclerosis relapse or exacerbation in the previous month. Exclusion Criteria: * Neurological disease other than multiple sclerosis. * Cognitive impairment preventing completion of tests or questionnaires. * Neurological, orthopedic, or visual impairments affecting gait.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ule Motion Lab

    RECRUITING

    Ponferrada, León, 24416, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.